Ping Yin

Ping Yin

Auto-generated profile, based on publicly available information

Ping Yin

Northwestern University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PYPing Yin
Ping Yin
MOMasanori Ono
Masanori Ono
MMMolly Moravek
Molly Moravek
JCJohn S. Coon
John S. Coon
ANAntonia Navarro
Antonia Navarro
SBSerdar E. Bulun
Serdar E. Bulun
Context: Uterine leiomyoma is the most common benign tumor in reproductive-age women. Using a dye-exclusion technique, we previously identified a side population of leiomyoma cells exhibiting stem cell characteristics. However, unless mixed with mature myometrial cells, these leiomyoma side population cells did not survive or grow well in vitro or in vivo. Objective: The objective of this study was to identify cell surface markers to isolate leiomyoma stem/progenitor cells. Design: Real-time PCR screening was used to identify cell surface markers preferentially expressed in leiomyoma side population cells. In vitro colony-formation assay and in vivo tumor-regeneration assay were used to demonstrate functions of leiomyoma stem/progenitor cells. Results: We found significantly elevated CD49b and CD34 gene expression in side population cells compared with main population cells. Leiomyoma cells were sorted into three populations based on the expression of CD34 and CD49b: CD34+/CD49b+, CD34+/CD49b−, and CD34−/CD49b− cells, with the majority of the side population cells residing in the CD34+/CD49b+ fraction. Of these populations, CD34+/CD49b+ cells expressed the lowest levels of estrogen receptor-α, progesterone receptor, and α-smooth muscle actin, but the highest levels of KLF4, NANOG, SOX2, and OCT4, confirming their more undifferentiated status. The stemness of CD34+/CD49b+ cells was also demonstrated by their strongest in vitro colony-formation capacity and in vivo tumor-regeneration ability. Conclusions: CD34 and CD49b are cell surface markers that can be used to enrich a subpopulation of leiomyoma cells possessing stem/progenitor cell properties; this technique will accelerate efforts to develop new therapies for uterine leiomyoma.

1 October 2025 in Physiological Reviews
Verified
Journal Article
Closed access
SBSerdar E. Bulun
Serdar E. Bulun
PYPing Yin
Ping Yin
JWJian-Jun Wei
Jian-Jun Wei
AZAzna Zuberi
Azna Zuberi
Takashi IIZUKATakashi IIZUKA
Takashi IIZUKA
ARAleksandar Rajkovic
Aleksandar Rajkovic
Uterine fibroids (leiomyomas), the most common tumors in women and those assigned female at birth, originate from myometrial smooth muscle cells and cause heavy menstrual bleeding, anemia, pelvic discomfort, pregnancy loss, and obstruction of labor in approximately a quarter of reproductive-age women. During each ovulatory cycle, the myometrium responds to the ovarian steroids, estradiol, and progesterone, via increased tissue stem cell proliferation to prepare for impending pregnancy, during which a somatic mutation may arise to initiate a tumor. Both the mutated smooth muscle cells and the adjacent tumor-associated fibroblasts lay down excessive quantities of extracellular matrix, providing a unique feature that led to naming these tumors “fibroids.” The most common somatic mutations in fibroids affect the Mediator complex subunit 12 ( MED12; 77%) and high-mobility group AT-hook 2/1 ( HMGA2/1; 10%) genes. Heterozygous mutations in MED12, a chromatin-associated protein, disrupt the attached CDK8 kinase module in the Mediator complex. MED12 mutations are associated with increased genomic instability, altered chromatin landscape and enhancer engagement, and increased responsiveness to progesterone. Progesterone and a small stem cell population in a fibroid are essential for tumor survival and growth. Progesterone, via its receptors in differentiated fibroid cell populations, activates the production of Wingless-type MMTV integration site family (WNT) ligands, cytokines, and other growth substances to act on adjacent stem cells in a paracrine fashion to support tumor growth. Suppression of estrogen or progesterone production and progesterone antagonists have been used for temporary shrinkage of these tumors and symptom relief. Here we provide an overview of these mechanisms and future approaches for prevention and medical management of uterine fibroids.

22 September 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
AZAzna Zuberi
Azna Zuberi
YHYongchao Huang
Yongchao Huang
ADAriel J. Dotts
Ariel J. Dotts
HWHelen Wei
Helen Wei
JCJohn S. Coon
John S. Coon
PYPing Yin
Ping Yin
Uterine leiomyomas cause heavy menstrual bleeding, anemia, and pregnancy loss in millions of women worldwide. Driver mutations in the transcriptional mediator complex subunit 12 (MED12) gene in uterine myometrial cells initiate 70% of leiomyomas that grow in a progesterone-dependent manner. We showed a distinct chromatin occupancy landscape of MED12 in mutant MED12 (mut-MED12) versus WT-MED12 leiomyomas. Integration of cistromic and transcriptomics data identified tryptophan 2,3-dioxygenase (TDO2) as the top mut-MED12 target gene that was significantly upregulated in mut-MED12 leiomyomas when compared with adjacent myometrium and WT-MED12 leiomyomas. TDO2 catalyzes the conversion of tryptophan to kynurenine, an aryl hydrocarbon receptor (AHR) ligand that we confirmed to be significantly elevated in mut-MED12 leiomyomas. Treatment of primary mut-MED12 leiomyoma cells with tryptophan or kynurenine stimulated AHR nuclear translocation, increased proliferation, inhibited apoptosis, and induced AHR-target gene expression, whereas blocking the TDO2/kynurenine/AHR pathway by siRNA or pharmacological treatment abolished these effects. Progesterone receptors regulated the expression of AHR and its target genes. In vivo, TDO2 expression positively correlated with the expression of genes crucial for leiomyoma growth. In summary, activation of the TDO2/kynurenine/AHR pathway selectively in mut-MED12 leiomyomas promoted tumor growth and may inform the future development of targeted treatments and precision medicine.

14 March 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
DIDeborah E Ikhena
Deborah E Ikhena
SLShimeng Liu
Shimeng Liu
SKStacy Kujawa
Stacy Kujawa
EEEcem Esencan
Ecem Esencan
JCJohn S Coon
John S Coon
PYPing Yin
Ping Yin
Context: Uterine leiomyomas are the most common type of gynecologic tumor in women. Objective: To determine the role of the cytokine receptor activator of nuclear factor κ-Β ligand (RANKL); its receptor, receptor activator of nuclear factor κ-Β (RANK); and the RANKL/RANK pathway inhibitor RANK-Fc in leiomyoma growth. Design: Messenger RNA (mRNA) or protein levels of RANKL, RANK, and proliferation markers cyclin D1 and Ki67 were assessed in various leiomyoma tissues and cell populations. Human xenograft experiments were performed to determine the effects of RANK-Fc on leiomyoma growth in vivo. Setting: Research laboratory. Patients: Twenty-four regularly cycling premenopausal women (age 28 to 49 years) who were not receiving hormone therapy. Interventions: None. Main Outcome Measure: Tumor growth in a murine xenograft model following targeting of the RANKL/RANK pathway with RANK-Fc. Results: RANKL mRNA levels in leiomyoma were significantly higher than those in myometrial tissues. The highest RANK levels were found in the leiomyoma stem cell population, which is deficient in progesterone receptor (PR). Conversely, the highest RANKL levels were found in the PR-rich leiomyoma intermediate cell (LIC) population. R5020, a PR agonist, specifically increased RANKL expression in LICs. RANK-Fc blocked RANKL-induced expression of the proliferative gene cyclin D1. Treatment with RANK-Fc also significantly decreased tumor growth in vivo and diminished the expression of proliferation marker Ki67 in tumors (P < 0.01; n = 4). Conclusions: Treatment with the RANKL/RANK pathway inhibitor RANK-Fc significantly decreased human leiomyoma cell proliferation and tumor growth. This suggests that the RANKL/RANK pathway could serve as a potential target for the prevention and treatment of uterine leiomyoma.

1 December 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
IOIjeoma Okeigwe
Ijeoma Okeigwe
SBSerdar Bulun
Serdar Bulun
SLShimeng Liu
Shimeng Liu
ARAlfred W Rademaker
Alfred W Rademaker
JVJohn S Coon V
John S Coon V
PYPing Yin
Ping Yin
Context: Uterine leiomyoma (fibroids) are the most common tumors in women. Recently, perilipin-2 (PLIN2) was identified as a critical target gene of the progesterone receptor; however, its function in the pathogenesis of fibroids is unknown. Objective: To determine the function of PLIN2 in leiomyoma cells Design: Tissue and primary cells from leiomyoma and myometrium were analyzed. PLIN2 function in leiomyoma was assessed using siRNA. RNA-sequencing was performed to identify genome-wide effects of PLIN2 depletion. Metabolic activity was measured using the Seahorse XF96 Analyzer. Real-time qPCR and immunoblotting were also performed. Setting: Laboratory Patients or Other Participants: . 41 premenopausal women undergoing surgery for fibroids Intervention(s): None Main Outcome Measure(s): Gene expression, oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and cell proliferation Results: PLIN2 gene expression was 2.4-fold lower in leiomyoma compared to adjacent myometrium, suggesting a link between PLIN2 deficiency and fibroids. 3877 genes were differentially expressed after PLIN2 knockdown. Gene Ontology analysis identified metabolism as the second highest biological process affected by PLIN2 depletion (P=1.6E-10). OCR (mitochondrial respiration) and ECAR (glycolysis) were significantly upregulated after PLIN2 knockdown; PLIN2 depleted cells had greater basal metabolic activity (P<.0001) and a higher metabolic stress response (P<.0001). Cell proliferation was also significantly increased after PLIN2 knockdown (P<.05). Conclusions: PLIN2 depletion increases mitochondrial respiration and glycolysis, suggesting that PLIN2 is a critical regulator of metabolic function in leiomyoma cells. PLIN2 deficiency also reprograms leiomyoma cells to a pro-proliferative phenotype. These findings introduce metabolomics as a novel area to explore to better understand leiomyoma tumorigenesis.

DPDiana C. Pacyga
Diana C. Pacyga
BRBrad A. Ryva
Brad A. Ryva
RERomana N Erbach
Romana N Erbach
SBSerdar E. Bulun
Serdar E. Bulun
PYPing Yin
Ping Yin
RSRita S. Strakovsky
Rita S. Strakovsky
Fibroid etiology is poorly understood but is likely hormonally mediated. Therefore, we evaluated associations between midlife phthalates (hormone-altering chemicals) and prior fibroid diagnosis, and considered differences by weight gain status. Women (ages: 45–54; n = 754) self-reported past fibroid diagnosis. We pooled 1–4 urines collected after fibroid diagnosis over the consecutive weeks to analyze nine phthalate metabolites and calculate relevant molar sums (e.g., di(2-ethylhexyl) phthalate, ΣDEHP; anti-androgenic phthalates, ΣAA; all metabolites, ΣPhthalates). Using Poisson regression, we evaluated associations between phthalate biomarkers and the risk of having fibroid diagnosis. We explored if associations differed by weight gain from age 18 to 45–54 or in women diagnosed with fibroids within 5 years of phthalate assessment. Our major finding was that women had a 13% (RR: 1.13; 95%CI: 1.02, 1.26) and 16% (RR: 1.16; 95% CI: 1.03, 1.31) greater risk of prior fibroid diagnosis for each two-fold increase in ΣDEHP or ΣAA, respectively. These associations were strongest in women who became overweight/obese from age 18 to 45–54 and in those diagnosed <5 years before phthalate assessment. Based on these results, prospective studies should corroborate our findings related to associations between phthalates and fibroids, and may consider evaluating the role that weight gain may play in these associations.